As Thousand Oaks-based Amgen prepares to spend $1.2 billion to buy leukemia drug maker Micromet, there are early signs that revenue from some of its biggest-selling drugs are stabilizing after years of declines and that biosimilars might present as much of an opportunity as a threat. Amgen, the world’s largest biotech company, said Jan. 26…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
